Rayence Co

Rayence Co OCF Margin

The Operating Cash Flow Margin of Rayence Co (228850.KQ) as of Nov 14, 2026 is 8.03 %. In the previous year, Operating Cash Flow Margin was 19.78 % — a change of -59.43% (lower).

OCF Margin

8.03 %

YoY

-59.43%

Last updated:

Operating Cash Flow Margin of Rayence Co is 2025 8.03 % . Operating Cash Flow Margin of Rayence Co was 2024 19.78 % . It decreases by -59.43% lower compared to the previous year.

The Rayence Co OCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF Margin
Date
OCF Margin
Jan 1, 2018
12.63 KRW
Jan 1, 2019
7.49 KRW
Jan 1, 2020
22.91 KRW
Jan 1, 2021
15.56 KRW
Jan 1, 2022
11.29 KRW
Jan 1, 2023
18.06 KRW
Jan 1, 2024
19.78 KRW
Jan 1, 2025
8.03 KRW
The Rayence Co OCF Margin history
YEAROCF MarginYoY
8.03 %-59.43%
19.78 %+9.55%
18.06 %+60.01%
11.29 %-27.47%
15.56 %-32.07%
22.91 %+205.74%
7.49 %-40.69%
12.63 %-34.74%
19.36 %+127.75%
8.50 %-21.12%
10.77 %+18.74%
9.07 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Rayence Co Stock analysis

What does Rayence Co do? Rayence Co., Ltd. generates revenue through the manufacturing and sale of x-ray detectors, including TFT and CMOS detectors under brand names such as 1012WCA, 17SCC/SGC, 1215CF, 1501CF, and 0712CF. The company also produces intra oral sensors branded as Ez1.0 and Ez1.5, along with mammography machines under the 1724CM and 2434CM series. These products are distributed to both domestic and international markets, serving healthcare providers and medical facilities that require diagnostic imaging equipment. The primary customers for Rayence's detectors and sensors are hospitals, clinics, and medical imaging centers seeking advanced x-ray technology. The firm's product portfolio targets the medical imaging segment, focusing on applications such as dental diagnostics with intra oral sensors and radiological imaging with mammography machines. Revenue streams are derived from direct sales of these branded products to healthcare institutions across multiple regions. Rayence's business model centers on selling specialized medical imaging equipment under its own brand names, with no mention of third-party partnerships or additional services. The company's revenue is directly tied to the purchase of its branded x-ray detectors, intra oral sensors, and mammography machines by healthcare providers who require high-quality diagnostic tools for patient care. Rayence Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Rayence Co stock

Operating Cash Flow Margin of Rayence Co is 8.03 % in 2025.

Operating Cash Flow Margin of Rayence Co changed from 19.78 % to 8.03 %, representing a -59.43% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Margin Rayence Co since 2006 – with annual values, charts, and detailed analysis.

OCF margin measures the percentage of revenue converted into operating cash flow. It indicates cash generation efficiency from core business operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow Margin's Rayence Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Rayence Co

All Key Metrics — Rayence Co